3
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’re hosting a virtual event tomorrow about the rise and unraveling of Moderna. My colleagues Jason Mast and Damian Garde will be there to talk about their coverage of the company, and you can ask them any questions! Register here.
The need-to-know this morning
- Biohaven Pharmaceuticals said its drug for spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease, was rejected by the FDA. The protracted review of the drug, called troriluzole, was controversial because Biohaven relied on historical data to demonstrate proof of efficacy. The FDA, in its letter to Biohaven, cited biases and confounding factors in those historical data as reasons for not approving the drug.
- After 12 years leading Utah-based “techbio” company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1.
- Amgen reported third-quarter earnings last night.
Novo CEO defends takeover bid for Metsera
As Novo Nordisk fights a bidding war against Pfizer to acquire the obesity biotech Metsera, its new CEO dismissed claims that its offer would run into regulatory issues and said that Metsera would complement its pipeline.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
